Last reviewed · How we verify
Mitoquinol
Mitoquinol is a Small molecule drug developed by University of Vermont. It is currently in Phase 1 development. Also known as: MitoQ.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Mitoquinol |
|---|---|
| Also known as | MitoQ |
| Sponsor | University of Vermont |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MitoQ for Fatigue in Multiple Sclerosis (MS) (PHASE1, PHASE2)
- Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 (PHASE2)
- Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women (NA)
- The Influence of Race and MitoQ Supplementation on Skin Blood Flow in the Cold (NA)
- An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness (PHASE1, PHASE2)
- MitoQ for the Treatment of Metabolic Dysfunction in Asthma (PHASE1)
- Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes (NA)
- MitoQ to Improve Vascular Funciton in Preeclampsia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitoquinol CI brief — competitive landscape report
- Mitoquinol updates RSS · CI watch RSS
- University of Vermont portfolio CI
Frequently asked questions about Mitoquinol
What is Mitoquinol?
Who makes Mitoquinol?
Is Mitoquinol also known as anything else?
What development phase is Mitoquinol in?
Related
- Manufacturer: University of Vermont — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: MitoQ
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing